INSM vs VRTX: How Insmed Incorporated and Vertex Pharmaceuticals Compare (2026)

Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

Reading it: VRTX is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. INSM and VRTX share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined INSM and VRTX exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Insmed Incorporated (Nasdaq: INSM) is a Bridgewater, New Jersey-based global biopharmaceutical company focused on serious and rare diseases, organized across three therapeutic areas: Respiratory, Immunology and Inflammation, and Neuro and Other Rare. Its commercial portfolio consists of two products. ARIKAYCE (amikacin liposome inhalation suspension) is an inhaled antibiotic approved in the United States, European Union, and Japan for refractory Mycobacterium avium complex (MAC) lung disease, a rare, chronic, and potentially fatal bacterial infection of the lungs. BRINSUPRI (brensocatib), a once-daily oral DPP1 inhibitor licensed from AstraZeneca in 2016, received FDA approval in August 2025 and European Commission approval in November 2025 as the first and only dedicated treatment for non-cystic fibrosis bronchiectasis, a progressive condition affecting an estimated 500,000 people in the United States alone. The pipeline includes TPIP, an inhaled treprostinil prodrug in Phase 3 development for pulmonary hypertension indications, as well as early-stage gene therapy programs in Duchenne muscular dystrophy and ALS. The company generates revenue entirely from product sales; it does not pay a dividend and remains net unprofitable as it invests heavily in commercial launches and clinical development.

Full INSM guide

Vertex Pharmaceuticals is a Boston-based biotechnology company that designs medicines targeting the root molecular cause of serious diseases rather than only their symptoms. Its foundation is cystic fibrosis (CF), a genetic disease in which a defective CFTR protein disrupts salt and water movement in cells, damaging the lungs and other organs. Vertex developed the first drugs that correct the underlying protein defect, progressing from Kalydeco to Orkambi and Symdeko and then to the breakthrough triple-combination Trikafta (marketed as Kaftrio in Europe), which treats the large majority of CF patients. In late 2024 it began rolling out Alyftrek, a next-generation once-daily successor designed to extend that franchise and its patent protection. Because CF is a rare disease with essentially no competing root-cause therapy, Vertex has enjoyed pricing power and durable, high-margin revenue.

Full VRTX guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• INSM drivers: BRINSUPRI as a potential blockbuster in a first-mover market; ARIKAYCE growth and label expansion potential.
• VRTX drivers: A durable, high-margin cystic fibrosis near-monopoly; Journavx opens a large non-opioid pain market.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: The stock carries a demanding valuation, trading at roughly 26x trailing price-to-sales as of late June 2026, a meaningful premium to biotech peers, which means any shortfall in BRINSUPRI uptake or payer coverage could trigger sharp multiple compression. For VRTX, the central risk is revenue concentration: cystic fibrosis still accounts for the overwhelming majority of Vertex's sales, so any disruption, whether a safety signal, a competing modulator, or pricing pressure, would hit the core disproportionately, and the newer products remain small by comparison.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick INSM if you believe its drivers more; VRTX if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the INSM and VRTX guides.

INSM. Insmed does not yet report a meaningful P/E ratio because the company remains net unprofitable, investing heavily in the BRINSUPRI commercial launch and clinical pipeline. Revenue growth is accelerating sharply: Q1 2026 revenues of $306 million exceeded Q1 2025 revenues of $92.8 million by more than 230%, driven by BRINSUPRI reaching $207.9 million in only its second full quarter on the market. The elevated price-to-sales multiple reflects market expectations that BRINSUPRI will scale toward blockbuster status, and investors are effectively paying a premium for a company that analysts do not expect to reach consensus profitability until approximately 2028.

VRTX. Vertex trades at a premium to the large-cap pharma average, with a trailing P/E near the high 20s and a forward P/E around 25, reflecting both its high margins and near-monopoly economics in cystic fibrosis and the market's expectation that the pain, cell-therapy, and pipeline programs will add a second and third growth engine. Because the CF franchise is so profitable and the balance sheet holds substantial net cash, much of the valuation debate is about how much credit to give unproven pipeline assets. Vertex does not pay a dividend, so returns depend entirely on earnings growth and multiple, which makes clinical and launch execution the key swing factors.

Headline figures (approximate, 2026-06-25): INSM shows full-year 2025 revenue ~$606 million, q1 2026 revenue (most recent quarter) ~$306 million, 2026 revenue guidance (brinsupri alone) at least $1 billion, net loss per share (q1 2026) -$0.76; VRTX shows revenue (fy 2025) ~$12.0 billion, revenue growth (fy 2025) ~9%, revenue guidance (fy 2026) ~$12.95 billion to $13.1 billion, trailing p/e (approx.) ~29x.

INSM and VRTX are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined INSM and VRTX exposure against your real portfolio. It is not an investment adviser.